Home > News > Venture firms still don't see the nanotech in biosciences
October 1st, 2003
Venture firms still don't see the nanotech in biosciences
Timing is everything, say Oregon's venture fund managers. The state of nanotechnology in the biosciences is too early for venture capital investing, believes Gerry Langeler, of Seattle-based OVP Venture Partners, the oldest venture firm in the Pacific Northwest, currently with $195 million to invest.
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014